Full text is available at the source.
Abstract
Lipid nanoparticles (LNPs) are a promising delivery platform that can enhance the performance of nucleic acid therapies.
- LNPs protect nucleic acid cargo and enable targeted delivery to specific tissues and cells.
- Raw material quality, formulation parameters, nanoparticle architecture, and biological context may significantly impact clinical outcomes.
- Key challenges include characterizing LNPs effectively, ensuring delivery specificity, and addressing scale-up and stability issues.
- Rational design principles and reproducible manufacturing practices are essential for advancing LNP technologies.
- Emerging applications of artificial intelligence could further improve LNP development and performance.
Simplified